We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Life Technologies’ SOLiD System Finds Mutations in Small Cell Lung Cancer Line
News

Life Technologies’ SOLiD System Finds Mutations in Small Cell Lung Cancer Line

Life Technologies’ SOLiD System Finds Mutations in Small Cell Lung Cancer Line
News

Life Technologies’ SOLiD System Finds Mutations in Small Cell Lung Cancer Line

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Life Technologies’ SOLiD System Finds Mutations in Small Cell Lung Cancer Line"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Applied Biosystems, part of Life Technologies Corporation has announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking.

The paper, authored by researchers from the Wellcome Trust Cancer Institute and co-authored by Applied Biosystems, demonstrates the potential for next-generation sequencing to provide unprecedented insights into mutational processes, cellular repair pathways and gene networks associated with cancer development.

“The publication of this paper emphasises the power that next-generation sequencing, such as Applied Biosystems’ SOLiD™ System, has to improve science’s understanding of disease and it’s potential to develop better diagnostics and therapeutic treatment,” said Kip Miller, President, Genetic Systems for Life Technologies. “Today’s SOLiD 3 Plus System offers even more capability and is faster, more robust and more economical than the SOLiD 2.0 System that generated the data in the paper.”

These impactful results were generated at the Sanger Institute using an early version of the SOLiD System. Massively parallel sequencing on Applied Biosystems’ SOLiD 2.0 System enabled the researchers to identify all of the mutations in the SCLC line NCI-H209 and compare them to a matched normal cell line.

Data identified several mutation signatures that reflect the wide range of carcinogens in tobacco smoke, which is notable because 90 percent of patients with SCLC smoked during their lives.
Advertisement